Search bioRxiv⌕ Search

Biology subjects

Jiang, X.-C.

Publications and source records attributed to Jiang, X.-C..

3 recordsLinked to original sources

Serine palmitoyltransferase-mediated de novo sphingolipid biosynthesis is required for normal insulin production and glucose tolerance

Aims/HypothesisThe importance for normal insulin secretion of ceramide synthesis is unclear. De novo ceramide synthesis requires serine palmitoyl transferase, SPT2, encoded by Sptl2. MethodsWe generated {beta}-cell-selective Sptl2 null mice by crossing animals with floxed alleles to mice expressing Cre recombinase from the Ins1 locus. Metabolic phenotyping, transcriptomic, functional analyses and histology were performed using standard approaches. ResultsIslets from Sptlc2{Delta}Ins1 mice displayed marked alterations in ceramide and sphingomyelin levels: ceramide content: p=0.016 and p=0.109; sphingomyelin content: p=0.016 and p=0.004 in Sptlc2{Delta}Ins1 vs Sptlc2CTL mice under regular and high fat diet, respectively, despite compensatory increases in the expression of enzymes in the salvage and sphingomyelinase pathways. Correspondingly, profound abnormalities were observed in glucose-regulated insulin secretion and glucose tolerance in vivo, both on a regular chow and high fat diet. These changes were associated with a drastic ([~]80%) lowering in {beta}-cell numbers, and a more minor increase in delta cell numbers. They were also preserved in animals maintained on a ketogenic diet, consistent with a cell autonomous effect on the {beta}-cell. Despite normal glucose-regulated intracellular calcium dynamics and insulin secretion, marked transcriptomic changes were observed in Sptlc2{Delta}Ins1 mouse islets, with affected GO terms including lysosome organisation and regulation of autophagy. Consistent with roles for compromised SPT2 function in diseased {beta}-cells, Sptl2 expression in Balbc and DBA2J mouse islets was lowered by a high fat-diet. Moreover, SPTLC2 mRNA tended to be lower, and SPTLC1 mRNA was significantly decreased, in islets from human subjects with type 2 diabetes versus normoglycemic individuals. ConclusionsPreserved de novo ceramide synthesis is required to maintain normal {beta}-cell mass and thus insulin secretion in mice. Therapeutic approaches which seek to target this process systemically using pharmacological SPT2 inhibitors should thus be treated with caution. Research in contextO_ST_ABS- What is already known about this subject?C_ST_ABSCeramides are key components of sphingolipid metabolism. Excess ceramide levels contribute to lipotoxicity and {beta}-cell apoptosis. -cell-restricted deletion of Cers2, which is responsible for the synthesis of very long ceramide chains, alters the insulin content of pancreatic islets and modifies glucose tolerance. Deletion of Cers 5 or 6, responsible for the synthesis of the long chains, has no effect. - What is the key question?What is the importance of de novo ceramide synthesis in {beta}-cells for the normal regulation of insulin production and glucose homeostasis? - What are the new findings?Inhibition of the de novo ceramide synthesis pathway in {beta}-cells, achieved by selective deletion of Sptlc2, encoding subunit 2 of the serine palmitoyltransferase (SPT) enzyme, induces a major alteration of glucose tolerance and insulin secretion. This is accompanied by a drastic reduction in {beta}-cell mass and islet insulin content. The remaining islets of Sptlc2{Delta}Ins1 display normal glucose-regulated intracellular calcium dynamics and insulin secretion despite imbalances in ceramide and sphingomyelin levels and substantial transcriptomic changes. Expression of SPTLC1, which encodes the other subunit of the SPT heterodimer, is reduced in islets from humans with type 2 diabetes, and a trend is observed towards lowered SPTLC2 expression. Taken together, these findings highlight the importance of de novo ceramide synthesis for normal {beta}-cell survival and function - How might this impact on clinical practice in the foreseeable future?By suppressing insulin production, global blockade or inhibition of SPT2, achieved with pharmacological approaches which seek to rescue insulin sensitivity in T2D, may be deleterious for glucose tolerance.

physiology↗

p.D372H: A novel SCN5A mutation associated with Brugada syndrome

BackgroundBrugada syndrome (BrS) is a genetic cardiac arrhythmia disorder inherited in an autosomal dominant manner, characterized by ST-segment elevation in the right precordial leads (V1-V3) on electrocardiograms (ECGs). This syndrome predominantly affects young individuals with structurally normal hearts and significantly increases the risk of ventricular arrhythmias and sudden cardiac death (SCD). The most common genotype found among BrS patients is caused by mutations in the SCN5A gene, which lead to a loss of function of the cardiac sodium (Na+) channel (Nav1.5) by different mechanisms. MethodsPlasmids containing SCN5A were constructed using PCR and site-directed mutagenesis to create the D372H mutation. HEK293 cells were cultured and transfected with the wild-type and mutant constructs. Patch-clamp recordings assessed sodium current characteristics. Confocal microscopy visualized channel localization. Quantitative RT-PCR analyzed mRNA expression levels, while Western blot evaluated protein expression using specific antibodies. We identified a novel missense mutation, D372H, in the SCN5A gene associated with Brugada syndrome. Functional assays in HEK293 cells expressing the D372H mutant revealed a near-complete loss of sodium currents. Subsequent experiments with co-transfection of WT and D372H plasmids demonstrated that co-expression led to a significant reduction in current density in WT-expressing cells (P < 0.05). The D372H mutation also resulted in a hyperpolarizing shift of approximately 20 mV in the voltage dependence of inactivation, while activation and recovery kinetics remained unaffected. Additionally, confocal microscopy showed reduced membrane localization of the D372H mutant, with a significant decrease in protein expression levels confirmed by Western blot and RT-qPCR analyses. ConclusionIn summary, our findings indicate that the D372H mutation in the Nav1.5 sodium channel leads to significant reductions in sodium current density, altered channel expression, and impaired membrane localization. These changes contribute to the pathophysiology of Brugada syndrome by disrupting cardiac action potential dynamics.

genetics↗

Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism in Mice

BackgroundSphingomyelin (SM) and cholesterol are two key lipid partners on cell membranes and on lipoproteins. Many studies have indicated the influence of cholesterol on SM metabolism. This study examined the influence of SM biosynthesis on cholesterol metabolism. MethodsInducible global Sms1 KO/global Sms2 KO mice were prepared to evaluate the effect of whole-body SM biosynthesis deficiency on lipoprotein metabolism. Tissue cholesterol, SM, ceramide, and glucosylceramide levels were measured. TG production rate and LDL catabolism were measured. Lipid rafts were isolated and LDL receptor mass and function were evaluated. Also, the effects of exogenous sphingolipids on hepatocytes were investigated. ResultsWe found that total SMS depletion significantly reduced plasma SM levels. Also, the total deficiency significantly induced plasma cholesterol, apoB, and apoE levels. Importantly, total SMS deficiency, but not SMS2 deficiency, dramatically decreased LDL receptors in the liver and attenuated LDL uptake through the receptor. Further, we found that total SMS deficiency greatly reduced LDL receptors in the lipid rafts which contained significantly lower SM and significantly higher glucosylceramide as well as cholesterol. Furthermore, we treated primary hepatocytes and Huh7 cells (a human hepatoma cell line) with SM, ceramide, or glucosylceramide, and we found that only SM could up-regulate LDL receptor levels in a dose-dependent fashion. ConclusionsWhole-body SM biosynthesis plays an important role in LDL-cholesterol catabolism. The total SMS deficiency, but not SMS2 deficiency, reduces LDL uptake and causes LDL-cholesterol accumulation in the circulation. Given the fact that serum SM level is a risk factor for cardiovascular diseases, inhibiting SMS2 but not SMS1 should be the desirable approach. Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=175 SRC="FIGDIR/small/527088v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@50757eorg.highwire.dtl.DTLVardef@51ad9dorg.highwire.dtl.DTLVardef@5d362corg.highwire.dtl.DTLVardef@18fbe63_HPS_FORMAT_FIGEXP M_FIG C_FIG

biochemistry↗